Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: First year's experience in a clinical center

Journal of Clinical Oncology

Volumn 19, Issue 9, 2001, Pages 2504-2508

  Tucker, R ^a   Coel, M ^a   Ko, J ^a   Morris, P ^a   Druger, G ^a   McGuigan, P ^a  

^a QUEEN S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CLINICAL PRACTICE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0035340692     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.9.2504     Document Type: Article

References (21)

1. The role of chemistry in positron emission tomography
2. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose
3. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma
4. Staging recurrent metastatic colorectal carcinoma with PET
5. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
6. Comparison of PET with conventional imaging techniques
7. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
8. Staging of primary colorectal carcinoma with flourine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
9. Comparative efficacy of positron emission tomography with FDG-PET and computed tomographic scanning in preoperative staging of non-small cell lung cancer
10. The role of FDG PET in the clinical management of head and neck cancer
11. Utility of 18F-FEG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
12. Cost-effectiveness of PET imaging in clinical oncology
13. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver
14. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer
15. A Delphi study to establish national cost-effectiveness research priorities for positron emission tomography
16. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
17. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma
18. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma
19. Whole body FDG-PET imaging for staging of the Hodgkin's disease and lymphoma
20. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis